Original articlePhenotypes of SMA patients retaining SMN1 with intragenic mutation
Introduction
Spinal muscular atrophy (SMA) is a neuromuscular disorder characterized by degeneration of anterior horn cells in the human spinal cord and subsequent loss of motor neuron [1]. SMA is clinically divided into five groups; type 0 (the most severe form with onset in the prenatal period; severe respiratory problems after birth), type 1 (Werdnig-Hoffman disease; a severe form with onset before 6 months of age; unable to sit unsupported), type 2 (Dubowitz disease; an intermediate form with onset before 18 months of age; able to sit unaided, but unable to stand or walk), type 3 (Kugelberg-Welander disease; a mild form with onset after 18 months of age; able to stand and walk unaided) and type 4 (the mildest form with age of onset from adolescence to adulthood) [2], [3].
Variations in the survival of motor neuron (SMN) genes, survival motor neuron 1 (SMN1) and survival motor neuron 2 (SMN2), are related to the development of SMA [4]. They reside on chromosome 5q13.2 as highly homologous gene copies [4]. SMN1 is now considered the disease-causing gene for SMA, because SMN1 is completely deleted in more than 95% of SMA patients and is deleteriously mutated (or carry deleterious intragenic mutation) in the remaining patients [4], [5]. SMN2 was considered as a dispensable gene because absence of SMN2 is frequently found in control individuals, but now it is considered to be a modifying factor of the SMA phenotype, because higher copy number of SMN2 may be related to milder SMA phenotypes [6], [7]. This correlation, however, is observed for homozygous SMN1 deleted patients. It is more difficult to conclude a relationship between SMN2 copy number and clinical severity in SMA patients with intragenic mutation [8]. It should also be noted here that all SMA patients, without exception, retain SMN2 [4].
The presence of SMN2 hampers detection of SMN1 mutations, because the two genes are highly homologous, differing in only five nucleotide base pairs in the region, intron 6 – exon 7 – intron 7 – exon 8 [4], [9]. To examine the presence or absence of SMN1 requires the detection of SMN1-specific nucleotides. Several assays using genomic DNA have been established for this purpose, including single-stranded conformation polymorphism (SSCP) analysis [4], restriction enzyme digestion analysis [9], and multiplex ligation-dependent probe amplification (MLPA) [10]. Even so, none of these methods can detect all SMN1 mutations that occur in SMA patients; they cannot detect intragenic SMN1 mutations.
For the detection of intragenic SMN1 mutations, two conditions need to be fulfilled: detection of a mutation in the SMN genes and assignment of the mutation to SMN1. To assign the mutation to SMN1, long-range (LR)- polymerase chain reaction (PCR) analysis of SMN1 in genomic DNA [11], [12] or reverse transcription (RT)-PCR analysis of SMN1 mRNA [13] have been used. Both methods can identify SMN1-specific nucleotides.
We have established accurate SMA diagnostic protocols, including SMN1 deletion detection and intragenic SMN1 mutation identification [8], [13], [14]. We have also established rapid SMA screening systems with filter paper for the detection of SMN1-deletion [15], [16], [17]. Rapid screening and accurate SMA diagnosis has been much more required compared to several years ago, because new effective drugs, such as nusinersen (Spinranza®), onasemnogene abeparvovec-xioi (Zolgensma®), and risdiplam (Evrysdi®) have appeared recently in the world [18], [19], [20].
In this study, we established an algorithm for SMA diagnostic procedures consisting of SMN1 deletion detection and intragenic SMN1 mutation identification, and then elucidated the relationship between clinical phenotypes and SMN2 copy number. We have detected 241 SMA patients in our laboratory, and identified 13 patients with intragenic SMN1 mutations among them. It is well-known that high SMN2 copy number modifies the phenotype of SMA patients with homozygous deletion of SMN1 [5]. However, in the patients with intragenic SMN1 mutation, the relationship between phenotype and SMN2 copy number remains unclear. Here, we compared “patients with homozygous SMN1 deletion” and “patients with intragenic mutation” in the relationship between clinical phenotypes and SMN2 copy number.
Section snippets
Patients
A total of 515 Japanese patients with suspicion of SMA were referred to our laboratory from 1996 to 2019. All patients presented with SMA-like symptoms; delayed developmental milestone, respiratory problem, muscle weakness, etc.
Prior to the genetic analysis, written informed consent was obtained from the patients or their parents. All procedures were reviewed and approved by the Ethics Committee of Kobe University Graduate School of Medicine, and were performed in accordance with the ethical
Results
This section consists of two kinds of data obtained in this study. One is comprehensive analyses of our dataset, which are described in 3.1–3.4. The other is individual analyses of five mutations identified in this study, which are described in 3.5–3.8.
Relationship between clinical phenotype and SMN2 copy number
Our previous data of SMA patient with homozygous SMN1 deletion was in complete agreement with the “inverse correlation between SMN2 copy number and clinical phenotype”, where the more SMN2 copy number, the less clinical severity [8], [26]. However, in the current study on the SMA patients with heterozygous mutations (SMN1 deletion and an intragenic SMN1 mutation), we were unable to find such an inverse correlation between SMN2 copy number and clinical phenotype.
Here, some patients with milder
Declaration of Competing Interest
The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.
Acknowledgements
We are indebted to the SMA patients who participated in this study. This research was supported by the Ministry of Education, Culture, Sports, Science and Technology, Japan, Grant No. 20K08197. Our sincere gratitude goes to Chiyo Hayashi for maintenance of the SMA database and for handling SMA patients’ samples. We thank Jeremy Allen, PhD, from Edanz Group (https://en-author-services.edanz.com/ac) for editing a draft of this manuscript.
We are also grateful to all doctors for their helpful
References (37)
- et al.
Spinal muscular atrophy: a clinical and research update
Pediatr Neurol
(2012) - et al.
Identification and characterization of a spinal muscular atrophy-determining gene
Cell
(1995) - et al.
Technical standards and guidelines for spinal muscular atrophy testing
Genet Med
(2011) - et al.
Correlation between SMA type and SMN2 copy number revisited: An analysis of 625 unrelated Spanish patients and a compilation of 2834 reported cases
Neuromuscul Disord
(2018) - et al.
Intragenic mutations in SMN1 may contribute more significantly to clinical severity than SMN2 copy numbers in some spinal muscular atrophy (SMA) patients
Brain Dev
(2014) - et al.
PCR-based DNA test to confirm clinical diagnosis of autosomal recessive spinal muscular atrophy
Lancet
(1995) - et al.
Multiplex ligation-dependent probe amplification improves diagnostics in spinal muscular atrophy
Neuromuscul Disord
(2006) - et al.
Genetic screening of spinal muscular atrophy using a real-time modified COP-PCR technique with dried blood-spot DNA
Brain Dev
(2017) - et al.
Two Japanese patients with SMA Type 1 suggest that axonal-SMN may not modify the disease severity
Pediatr Neurol
(2015) - et al.
SMA mutations in SMN Tudor and C-terminal domains destabilize the protein
Brain Dev
(2017)
Spinal muscular atrophy carriers with two SMN1 copies
Brain Dev
The gene for neuronal apoptosis inhibitory protein is partially deleted in individuals with spinal muscular atrophy
Cell
Clinical phenotypes of spinal muscular atrophy patients with hybrid SMN gene
Brain Dev
Direct interaction of the spinal muscular atrophy disease protein SMN with the small nucleolar RNA-associated protein fibrillarin
J Biol Chem
A new splice site mutation in the SMN1 gene causes discrepant results in SMN1 deletion screening approaches
Neuromuscul Disord
Spinal muscular atrophy: from gene discovery to clinical trials
Ann Hum Genet
Review of spinal muscular atrophy (SMA) for prenatal and pediatric genetic counselors
J Genet Couns
Spinal muscular atrophy: diagnosis and management in a new therapeutic era
Muscle Nerve
Cited by (10)
Advances in the Therapy of Spinal Muscular Atrophy
2021, Journal of PediatricsCitation Excerpt :The location and type of mutation seem to affect the phenotype, although conclusions are limited by the small number of patients. Despite having only 1 copy of SMN2, patients with SMA with SMN1 exon 1 missense variants (c.5C>G, c.5C>T, and c.38C>G) had a milder phenotype within a cohort of Japanese patients and a separate cohort of Brazilian patients with SMA, whereas frameshift or nonsense mutations involving more highly conserved regions of SMN1, such as the C-terminus, generally, but not always, resulted in more severe phenotypes.66,67 The SMN2 variants c.859G>C (exon 7) and A-44G (intron 6) are associated with milder phenotypes, have not been identified in severe SMA, or in those with phenotypes concordant with their SMN2 copy number, and when present increase the amount of full length SMN transcript by approximately 20%.68-70
The nexus between RNA-binding proteins and their effectors
2023, Nature Reviews GeneticsMolecular-genetic study of SMN1 and SMN2 genes associated with spinal muscular atrophy in individuals with infertility prior to in vitro fertilization
2023, Obstetrics, Gynecology and ReproductionChanges in the Incidence of Infantile Spinal Muscular Atrophy in Shikoku, Japan between 2011 and 2020
2022, International Journal of Neonatal Screening